Reprogramming metabolic pathways in vivo with CRISPR/Cas9 genome editing to treat hereditary tyrosinaemia

Many metabolic liver disorders are refractory to drug therapy and require orthotopic liver transplantation. Here we demonstrate a new strategy, which we call metabolic pathway reprogramming, to treat hereditary tyrosinaemia type I in mice; rather than edit the disease-causing gene, we delete a gene...

Descripción completa

Detalles Bibliográficos
Autores principales: Pankowicz, Francis P., Barzi, Mercedes, Legras, Xavier, Hubert, Leroy, Mi, Tian, Tomolonis, Julie A., Ravishankar, Milan, Sun, Qin, Yang, Diane, Borowiak, Malgorzata, Sumazin, Pavel, Elsea, Sarah H., Bissig-Choisat, Beatrice, Bissig, Karl-Dimiter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5013601/
https://www.ncbi.nlm.nih.gov/pubmed/27572891
http://dx.doi.org/10.1038/ncomms12642

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5013601/
https://www.ncbi.nlm.nih.gov/pubmed/27572891
http://dx.doi.org/10.1038/ncomms12642

Ejemplares similares